SSS Sunvest Minerals Corp

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT" or the "Corporation") a
life sciences company developing stem cell-related technologies, today announced
a joint-venture agreement with ReNeu Inc. of Calgary, AB, Canada, ("ReNeu") and
NexGen Medical Systems, Inc. of Melbourne, FL, USA ("NexGen").


ReNeu is a company formed to commercialize drug-based therapies to treat central
nervous system disorders in combination with devices and processes for
direct-to-brain administration. Subject to the definitive agreement, SCT and
NexGen will license their respective technologies to ReNeu under world-wide,
royalty-free licenses for the use of NexGen's FDA-cleared EViTAR(TM) line of
proprietary intracranial delivery systems and SCT's NTx-265, -428 and -488
covering the proprietary use of drugs for the regeneration of endogenous neural
stem cells. 


To the knowledge of the Corporation the EViTAR(TM) intracranial delivery system
is the only FDA-cleared Class II medical device currently indicated for the
injection of material into the brain during intracranial procedures. It is
designed for site-specific, low-volume, high-concentration delivery of drugs to
target tissues in the brain of patients suffering from stroke, neurodegenerative
disease, and tumors. SCT's NTx-265 is a therapeutic regimen of approved and
clinically well-defined drugs that include human Chorionic Gonadotropin ("hCG")
and erythropoietin ("EPO") for the regeneration of neural stem cells in patients
following stroke, traumatic brain injury and other neurological conditions. 


"ReNeu's perceptive innovation that the combination of SCT's award-winning,
proprietary discoveries by Dr. Sam Weiss, Director of the Hotchkiss Brain
Institute, if administered in a direct-to-brain process, holds the promise of
delivering the regenerative results that Dr. Weiss' discovery originally
proposed. NexGen's EViTAR family would appear to be an ideal vehicle for the
clinical expansion of the SCT products and we are enthusiastic about its
prospects," said David Allan, Executive Chairman of SCT.


Under the Letter of Agreement SCT will own 50% of the joint-venture for which
the definitive agreement is anticipated within 60 days, subject to final
due-diligence and usual conditions being met.


"The breakthrough benefit to patients that could be expected to result from a
positive clinical demonstration from the combination of these two critical
elements for the treatment of neurologically degenerative diseases could be of
significant importance for the treatment of patients with stroke and other
neurological conditions," said Dr. Joseph Tucker, founding CEO of ReNeu. "The
most effective preclinical treatments from Dr. Weiss' work licensed to SCT were
the direct-to-brain approaches, which clearly indicated the prospect of
important benefit to patients when developed clinically. At the time, SCT
proceeded in its clinical development with systemic rather than site-specific
administration because of the absence of availability of a direct-to-brain
approach, with the consequence that only limited amounts of SCT's drug
combination reached the brain and equivocal clinical outcomes were achieved. We
have high expectations that this fortuitous combination of these two novel
approaches could have an importantly different and positive outcome." 


"NexGen is very excited about this collaboration with SCT and ReNeu," said John
Kucharczyk, CEO of NexGen Medical Systems. "The novel treatment methods have the
potential to introduce entirely new therapies for several neurological diseases
and disorders. NexGen's proprietary EViTAR(TM) neurocatheters are designed for
delivery of therapeutic agents directly to target tissues in the brain and
spinal cord, which is expected to significantly reduce side-effects associated
with systemic delivery of drugs," Kucharczyk added.


ReNeu's initial board will be composed of David Allan, Executive Chairman of
Stem Cell Therapeutics, Dr. John Kucharczyk, CEO of NexGen Medical Systems, Dr.
Brad Thompson, Chairman & CEO of Oncolytics Biotech and Dr. Joseph Tucker,
founding CEO of ReNeu. The Company intends to vigorously pursue regulatory
approval to move the combined technologies into clinical trials with a target of
clinical initiation in 2014.


SCT will retain all rights to its endogenous stem cell-stimulating technology
other than direct-to-brain administration.


About Stem Cell Therapeutics Corp.: 

Stem Cell Therapeutics Corp. develops stem cell-based therapeutics through
partnerships with research institutions and technology transfer organizations.
SCT's objectives include the sourcing and acquisition of additional stem
cell-related development opportunities, and securing capital for the advancement
of its licensed or acquired products. SCT is currently conducting a Phase II
clinical trial in traumatic brain injury with NTx(R)-428 designed to
characterize the ability of hCG followed by EPO to promote neurological and
functional recovery of the brain following moderate-to-serious acute cortical
(white matter) injury to the brain. For more information visit:
www.StemCellThera.com.


About ReNeu Inc.:

ReNeu Inc. is a biotechnology company developing novel therapies for the
treatment of central nervous system disorders. Our proprietary approach is to
enhance brain remodeling and plasticity by administering neurogenesis-promoting
drugs directly into the brains of patients. Our lead product, UnDo(TM), aims to
improve brain and motor function in victims of stroke. For more information
visit: www.ReNeuInc.com.


About NexGen Medical Systems, Inc.: 

NexGen Medical Systems, Inc. is a private, development-stage Florida-based
company that is developing catheter-based medical device products for
therapeutic interventions in radiology, vascular surgery, and neurosurgery. The
Company is commercializing an integrated medical device product line for removal
of blood clots from head, neck, and peripheral vessels. The Company also
develops access devices and technologies for the treatment of neurological
diseases and disorders. NexGen is incorporated in Delaware and commenced
operations in 2005. For more information visit: www.NexgenMedsystem.com.


Caution Regarding Forward-Looking Information: 

This press release may contain forward-looking statements, which reflect SCT's
current expectation regarding future events. These forward-looking statements
involve risks and uncertainties that may cause actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include, but are not limited to, SCT's ability to obtain financing in
connection with the proposed arrangement; uncertainties as to the timing of the
arrangement; the satisfaction of the conditions precedent to the completion of
the arrangement; changing market conditions; the successful and timely
completion of pre-clinical and clinical studies; the establishment of corporate
alliances; the impact of competitive products and pricing; new product
development risks; uncertainties related to the regulatory approval process or
the ability to obtain drug product in sufficient quantity or at standards
acceptable to health regulatory authorities to complete clinical trials or to
meet commercial demand; and other risks detailed from time to time in SCT's
ongoing quarterly and annual reporting. Except as required by applicable
securities laws, SCT undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Stem Cell Therapeutics Corp.
David Allan
Executive Chairman
+1 647 258 4325
DAllan@StemCellThera.com
WWW.StemCellThera.com

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024